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Abstract 
 
Genetic variations in G protein-coupled receptor (GPCR) genes can disrupt receptor function 
in a wide variety of human genetic diseases, including platelet bleeding disorders. Platelets 
are critical for haemostasis with inappropriate platelet activation leading to the development 
of arterial thrombosis, which can result in heart attack and stroke whilst decreased platelet 
activity is associated with an increased risk of bleeding.  GPCRs expressed on the surface of 
platelets play key roles in regulating platelet activity and therefore function. Receptors 
include purinergic receptors (P2Y1 and P2Y12), proteinase-activated receptor (PAR1 and 
PAR4) and thromboxane receptors (TPα), among others.  Pharmacological blockade of these 
receptors forms a powerful therapeutic tool in the treatment and prevention of arterial 
thrombosis. With the advance of genomic technologies, there has been a substantial increase 
in the identification of naturally occurring rare and common GPCR variants. These variants 
include single-nucleotide polymorphisms (SNPs) and insertion or deletions that have the 
potential to alter GPCR expression or function. A number of defects in platelet GPCRs that 
disrupt receptor function have now been characterized in patients with mild bleeding 
disorders. This review will focus on rare, function-disrupting variants of platelet GPCRs with 
particular emphasis upon mutations in the P2Y12 receptor gene that affect receptor traffic to 
modulate platelet function. Further this review will outline how the identification and 
characterization of function-disrupting GPCR mutations provides an essential link in 
translating our detailed understanding of receptor traffic and function in cell line studies into 
relevant human biological systems.   
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Introduction 
Blood platelets play a critical role in the cessation of bleeding upon vascular injury. However, 
they also contribute to the low-grade inflammation that drives endothelial dysfunction and the 
formation of occlusive thrombi upon atherosclerotic plaque rupture (1). Under physiological 
conditions the continual release of inhibitory prostaglandins and nitric oxide by the 
endothelium prevents platelet activation and adherence to the vessel wall (2). Upon vessel 
wall damage, platelets bind to exposed collagen, become activated and release a number of 
stimulatory mediators including adenosine diphosphate (ADP) which feedback in an 
autocrine manner (3). The subsequent release of soluble platelet agonists promotes platelet 
aggregation to ensure rapid haemostasis at the site of injury and the formation of a stable clot, 
preventing further blood loss.  
Platelet activation is a tightly regulated process with changes in platelet reactivity 
significantly impacting upon the haemostatic process. Increased platelet activity, for example 
at the site of atherosclerotic plaque rupture, may result in myocardial infarction or stroke. 
Conversely decreased platelet activity is associated with an increased risk of bleeding.  
Platelet G protein-coupled receptors (GPCRs) are critical regulators of platelet function with 
pharmacological blockade of these receptors a powerful therapeutic tool in the treatment and 
prevention of arterial thrombosis (4).  In order to optimise the use of existing antiplatelet 
drugs and to develop new therapies, more detailed knowledge of the molecular mechanisms 
that regulate GPCR-mediated platelet function is still required. 
 
The platelet P2Y12 receptor – a key player in platelet activation  
Platelet activation is a multistep process consisting of platelet adhesion, shape change, 
granule secretion and aggregation. It is mediated by a number of cell surface receptors, 
including integrins and ion channels as well as GPCRs (3). Of the GPCRs present on the 
platelet surface, the key receptors involved in platelet activation include the protease 
activated receptor (PAR)1 and PAR4, the purinergic P2Y1 and P2Y12 and the TP-α 
thromboxane (4).   The P2Y12 receptor plays a pivotal role in platelet activation (reviewed in 
(1)). Stimulation of P2Y12 receptors by ADP released from the dense granules of activated 
platelets results in sustained platelet aggregation and secretion (5). In addition, the P2Y12 
receptor plays an essential role in potentiating platelet responses initiated by other important 
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platelet activators such as thrombin and thromboxane(6). Pharmacological blockade of the 
P2Y12 receptor is a powerful antiplatelet strategy in the treatment and prevention of arterial 
thrombosis associated with coronary atherosclerosis. Clopidogrel, prasugrel and ticagrelor are 
potent inhibitors of the P2Y12 receptor with efficient antithrombotic activity reducing the rate 
of thrombotic events in acute coronary syndrome patients (7).  
In order to minimize inappropriate platelet recruitment and activation at the site of a growing 
thrombus, platelet ADP responsiveness is tightly regulated in human platelets (8-12). P2Y12 
receptor responsiveness rapidly desensitizes in human platelets (13). Previous studies in cell 
lines have identified that G protein-coupled receptor kinase (GRK)2- and GRK6-dependent 
phosphorylation of the P2Y12 receptor is required for arrestin association and desensitization 
(9). Following removal of ADP there is a rapid resensitization of P2Y12 receptor 
responsiveness in human platelets (11). In order to resensitize, the P2Y12 receptor internalizes 
following agonist addition and then recycles back to the cell membrane following removal of 
ADP (11).  The P2Y12 receptor, similarly to P2Y1, internalizes via clathrin- and dynamin-
mediated endocytosis (14). Intriguingly these two purinergic receptors appear to sort into 
distinct membrane clathrin coated pits, an observation that has been reported for other 
GPCRs (15). The mechanisms underlying P2Y12 receptor internalization are complex and, as 
with receptor desensitization, are mediated in part by GRKs and arrestin (14,16,17). The 
small GTP-binding protein ARF6 (ADP-ribosylation factor 6) also plays a role in the 
internalization of P2Y12 receptors in human platelets (16). Activation of P2Y12 receptors 
stimulates ARF6 activity which in turn regulates Nm23-H1, an nucleoside diphosphate kinase 
to facilitate dynamin-dependent fission of clathrin-coated vesicles.  Following internalization, 
the P2Y12 receptor undergoes rab5-dependent trafficking to a sorting compartment from 
which it is rapidly recycled (18). Rapid recycling of the P2Y12 receptor had previously been 
described in human platelets although the mechanism at that time was unclear (8). Blockade 
of receptor internalization or subsequent recycling results in attenuation of receptor 
resensitization in human platelets (11). Our understanding of this process has been further 
advanced by the study of patients with rare genetic variations in the platelet P2Y12 receptor.  
 
Rare genetic variations in platelet GPCRs: shining a light into the receptor / structure 
function relationship in vivo 
Genetic variations in GPCR genes that disrupt receptor function can lead to a wide variety of 
human genetic diseases (reviewed in (19)and (20). Advances in genomic technologies have 
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led to a substantial increase in the identification and characterization of naturally occurring 
rare and common GPCR variants. Such variants can include single-nucleotide 
polymorphisms (SNPs) and gene insertions or deletions with the potential to alter GPCR 
function and expression. In some cases these variants can inactivate receptor proteins, often 
referred to as loss-of-function (LOF) mutations (21).  Heterozygous expression of LOF 
mutations can in some cases result in a dominant negative phenotype, with expression of the 
LOF variant impairing the function of the wild type receptor (as reviewed in (22)).  In 
contrast to LOF mutations constitutively active mutants (CAMs) will lead to agonist-
independent signalling. Both animal models and in vitro studies have commonly been used to 
characterize the molecular pathologies that underlie these naturally occurring GPCR 
mutations with inactive, overactive, or constitutively active receptors identified that result in 
pathology. Receptor variants may alter receptor expression, basal activity, ligand binding, G-
protein coupling, receptor desensitization and receptor recycling (21). An ever increasing 
variety of GPCRs are affected by genetic variation that results in human pathology (reviewed 
in (20) and (19)) including variations in platelet GPCRs affecting platelet function (reviewed 
in (22)).  
The detailed and systematic study of patients with bleeding disorders has continued to 
provide significant information regarding platelet GPCR function(23). Indeed the P2Y12 
receptor was initially cloned following the study of a patient with a bleeding history and a 
loss of function variation in the P2Y12R gene that encodes P2Y12(24).  As part of the 
Genotyping and Phenotyping of Platelets consortium (GAPP) a series of rare genetic 
variations causing defects within platelet proteins(25), including GPCRs(22) have been 
identified.  GAPP have recruited a cohort of patients with symptoms of mild, lifelong 
bleeding but no demonstrable defect in either platelet number or coagulation cascade 
function. The key signalling pathways responsible for loss of platelet function are studied in 
samples derived from individual patients. Knowledge of the defective pathways allows 
targeted sequencing of a subset of genes with the purpose of identifying LOF variants 
involved in forming the signalling pathway which may underlie the platelet dysfunction (26).  
Through this and similar patient-led phenotypic approaches, LOF variants in a number of 
platelet GPCRs including the P2Y12 (see Figure 1 (27-32)), PAR4 (33) and TP-α receptors 
(34,35) have been identified. Further detailed analysis of the 1,000 Genomes and ESP6500 
databases has highlighted a host of potentially damaging variants in other platelet GPCR 
genes(23). Subsequent analysis of receptor function and expression of mutant receptor 
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variants in model cell lines has ultimately provided significant information regarding 
structure-function relationships.  Specific mutations have now been shown to affect platelet 
surface receptor expression, ligand binding, G protein-coupling, receptor internalization and 
receptor sorting (reviewed in (22) and (36)).    
This review will concentrate on the consequences of mutations which specifically affect 
P2Y12R surface expression, internalization and traffic that have in turn provided important 
insights into how these clinically important GPCRs function in vivo.  
The DRY motif: the case of the R122C P2Y12 receptor variant 
Recently solved agonist- and antagonist-bound crystal structures of a number of GPCRs  
including the P2Y12 receptor(37,38) (39)have significantly enhanced our understanding of 
ligand / receptor interaction and revealed an overall receptor activation mechanism (40,41). A 
number of conserved regions show distinct interaction patterns in the inactive receptor (R) 
versus active receptor (R*) conformations (40,42,43).  These motifs are believed to be critical 
regulators of the receptor activation process with one of these composed of the amino acids 
glutamic acid/aspartic acid– arginine–tyrosine, making up the E/DRY motif (44,45). This 
motif is located at the boundary between transmembrane helix 3 (TM3) and intracellular loop 
2 (ICL2) and is one of the most highly conserved in class A rhodopsin-like GPCRs with the 
arginine (Arg) being found in close to 100% of these receptors (44), including the P2Y12 
receptor(45). The consensus derived mostly from studies on α1B and β2 adrenoceptors is that 
the basic Arg forms a stabilizing intrahelical salt-bridge with the neighbouring Asp or Glu, 
and interhelical hydrogen bonds with another charged residue at the base of TM6, thereby 
constraining the GPCR in an inactive (R) conformation(42,43). 
The in vivo importance of the E/DRY motif was demonstrated in a patient who had a lifelong 
history of spontaneous bleeding, and haemorrhage upon surgical challenge (31). This patient 
who was homozygous for an Arg122Cys substitution within the DRY motif of the P2Y12 
receptor (DRYDCY) displayed significantly reduced platelet aggregation in response to 
ADP (see Figure 1).  Further analysis of platelets derived from the patient revealed a 
significant reduction in surface P2Y12 receptor expression. Two other class A GPCRs have 
also been identified with naturally occurring mutations in the central Arg of the DRY motif 
which include the vasopressin V2 (46) (47) and the gonadotropin-releasing hormone 
receptors (GnRH) (48,49). In the case of the GnRH receptor, two mutations (Arg139His or 
Arg139Cys) result in a loss of agonist-stimulated receptor activity and hypogonadotropic 
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hypogonadism in the patient. For mutations in the V2 vasopressin receptor, the situation is 
more complicated with mutations in the DRY motif leading to two different diseases with 
opposite clinical outcomes. An Arg137His mutation leads to nephrogenic diabetes insipidus 
(50), while an Arg137Cys/Lys mutation leads to a nephrogenic syndrome of inappropriate 
antidiuresis (46).  
Intriguingly the P2Y12 receptor crystal structure shows that this receptor lacks some 
regulatory features conserved in many class A GPCRs. For example an “ionic lock” between 
the bottom of TM3 and TM6 seen in some GPCRs (51) is not present in the P2Y12 receptor 
(37). This lock is thought to stabilise the inactive conformation of a GPCR in the absence of 
agonist ligand. In line with these structural observations, close examination of P2Y12 receptor 
signalling in 1321N1 cells shows that the receptor exhibits agonist-independent constitutive 
activity(31,52).  Over-expression of the Gi-coupled P2Y12 receptor leads to an attenuation of 
forskolin-stimulated adenylate cyclase responsiveness in the absence of ADP (31) (52). This 
reduction in forskolin responsiveness is even more pronounced in cells expressing the 
Arg122Cys P2Y12 variant receptor. Similarly the Arg137Cys/Lys variants of the V2 
vasopressin receptor are also characterized by an elevated basal agonist-independent signal 
(53). Importantly ticagrelor is the only P2Y12 receptor antagonist to block the constitutive 
agonist-independent activity of the wild type P2Y12 receptor and may contribute to the 
improved clinical efficacy of this antiplatelet drug versus other clinically used P2Y12 receptor 
antagonists (52).   
In relation to receptor traffic, the wild type P2Y12 receptor undergoes significant agonist-
independent internalization where it colocalizes with transferrin, a marker for early and 
recycling endosomes (31). This pool of receptor, which recycles in a rab4-dependent manner, 
can readily recycle back to the cell surface (18). Whether like other platelet GPCRs (54,55) 
this agonist-independent traffic may provide an internal pool of receptor able to mobilise to 
the cell surface and support receptor signalling requires further study. In cell lines the 
Arg122Cys P2Y12 receptor also internalizes in an agonist-independent manner although at a 
faster rate than the wild type receptor(31). Interestingly, mutation in the DRY motif of the V2 
vasopressin receptor (Arg137His) promotes agonist-independent internalization followed by 
intracellular accumulation (50).  Like the Arg137His vasopressin receptor, the Arg122Cys 
P2Y12 receptor variant undergoes rapid agonist-independent loss of surface receptor(31). 
When combined with signalling data outlined above, disruption of the DRY motif therefore 
appears to prevent stabilization of the P2Y12 and other GPCRs in an inactive conformation in 
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the absence of agonist thereby enhancing agonist-independent receptor activity and 
internalization. 
Following agonist-independent internalization a significant proportion of the Arg122Cys 
P2Y12 receptor variant, as in platelets, accumulates intracellularly (31). For many variant 
GPCRs, including in platelets variants of the TP thromboxane receptor (35) and PAR4(33), 
the receptor accumulates in the Golgi/ER suggestive of an impairment of receptor export. 
This was not the case with the Arg122Cys P2Y12 variant receptor with no evidence of co-
localization with Golgi/ER markers. In fact, the Arg122Cys P2Y12 receptor variant is targeted 
to a distinct endocytic compartment, where unlike the wild type P2Y12 receptor, it colocalizes 
with lysosomal markers (31). The specific molecular regulators of this process are currently 
unknown. The variant does possess a novel cysteine that could lead to the introduction of 
novel disulfide cysteine–cysteine intramolecular bonds potentially promoting this aberrant 
traffic. However no obvious differences in molecular masses of the Arg122Cys P2Y12 
receptor have been reported which would preclude lack of novel protein-protein bonds.  
Further there are no obvious interaction motifs that could explain changes in receptor 
trafficking that are proximal to the DRY motif. Given the large number of interacting 
proteins that could potentially regulate the Arg122Cys P2Y12 variant being preferentially 
targetted to lysosomes (56), further detailed cellular studies are still required to address this 
question.  
 
The integrity of the PDZ-binding motif of the P2Y12R is essential for normal platelet 
receptor function 
A number of SNPs within GPCRs appear to modulate agonist-dependent receptor traffic. For 
example in the human β1-adrenoceptor Ser49Gly, a SNP located in the N-terminus, displays a 
distinct trafficking phenotype (57) with the variant exhibiting increased basal and agonist-
stimulated adenylyl cyclase activity as well as enhanced agonist-induced downregulation 
(58). For the β2-adrenoceptor the picture is more complex with an Arg16Gly variant receptor 
displaying enhanced agonist-promoted downregulation whilst a Gln27Glu polymorphism is 
resistant to degradation (reviewed in (59). Such SNPs that can alter agonist-dependent traffic 
have the potential to impact upon pharmacotherapy directed at these GPCRs. For example the 
Arg16Gly β2-adrenoceptor receptor, which is associated with reduced lung function and 
familial nocturnal asthma, is also commonly resistant to some β2-adrenoceptor agonists (60).  
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This agonist resistance has been attributed to enhanced agonist-induced receptor loss.  
Similarly a variant of the µ-opioid receptor (L83I) morphine is more liable to internalize in 
response to morphine, unlike the wild-type receptor that undergoes significantly less 
morphine-stimulated internalization (61). The presence of this SNP within an individual may 
consequently affect the development of tolerance and analgesic responses. Therefore SNPs 
which can affect normal agonist-stimulated changes in surface receptor expression have the 
potential to alter drug responsiveness.   
In relation to the platelet P2Y12 receptor, a particularly novel mutation identified through 
GAPP was in a patient with mild bleeding who was heterozygous for a Pro341Ala 
substitution (32). This SNP was of particular interest since the mutation is located within a 
putative postsynaptic density 95/disc large/zonula occludens-1 (PDZ) binding sequence at the 
extreme C terminus of the P2Y12 receptor (see Figure 1). PDZ ligands consist of a short 
amino acid sequence and are found at the extreme C-terminus of a large number of proteins 
including more than 30 GPCRs (56,62).  These ligands can bind to a number of PDZ domain-
containing regulatory proteins with these interactions regulating various aspects of receptor 
function including stabilization, signaling and trafficking (62,63).  P2Y12 receptor signalling 
and ligand binding was significantly diminished in platelets expressing the Pro341Ala 
variant(32).  Despite a large number of cell line studies which have highlighted the 
importance of PDZ interactions (62), this was the first report of a naturally occurring 
mutation in a PDZ ligand in vivo demonstrating the importance of this motif to receptor 
function. Further study revealed that alongside deficits in receptor function, agonist-
dependent P2Y12 receptor traffic was also significantly compromised in platelets expressing 
the Pro341Ala variant. Accompanying this change in receptor traffic, agonist-induced 
changes in receptor activity were also abrogated with minimal resensitization of receptor 
function following ADP-stimulated receptor desensitization.    
Subsequent studies in cells transfected with the variant Pro341Ala P2Y12 receptor revealed 
that the variant receptor was retained intracellularly in a rab-7 positive compartment which 
colocalized with markers of the trans-Golgi network (TGN). The Pro341Ala P2Y12 receptor 
was not able to recycle and resensitize following agonist exposure (18,32).  This was in 
contrast to the wild type receptor which recycles back to the cell surface in a rab4/11-
dependent manner rapidly following agonist-dependent internalization facilitating receptor 
resensitization (18).  Therefore the integrity of the PDZ-ligand of the P2Y12 receptor was 
essential for normal agonist-induced traffic. 
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PDZ-binding proteins play an essential role in maintaining platelet P2Y12R activity 
Given the in vivo demonstration of the critical importance of the PDZ-binding motif, a 
subsequent proteomic screen revealed a series of binding partners that specifically interacted 
with the C-terminus of the P2Y12 receptor including the PDZ-binding protein, Na+/H+ 
exchanger regulatory factor (NHERF). Interestingly the PDZ ligand and the presence of the 
Pro341 residue limited the number of proteins capable of interacting with the P2Y
12
 receptor, 
with a significant increase in binding partners following its substitution (M.R. Cunningham 
and S.J. Mundell, unpublished work).  This result would imply that the integrity of the PDZ 
ligand is essential for recognition by a specific subset of PDZ domain-containing proteins 
that regulate receptor function and may well explain the differential endosomal sorting of the 
Pro341Ala -variant (18,32).   Addition of a CFP-tag onto the C-terminus of the receptor also 
alters the complement and number of P2Y
12
 receptor interacting partners (M.R. Cunningham 
and S.J. Mundell, unpublished work) highlighting the potential pitfalls of adding bulky 
proteins onto the C-terminus of a GPCR.  
Further studies have confirmed the ability of NHERF isoforms (NHERF1 and NHERF2) to 
bind specifically to the C-tail PDZ ligand of the P2Y12 receptor (64), thus supporting the 
proteomic screen.  These proteins have now been shown to regulate the surface expression 
and activity of numerous GPCRs (65). NHERF1 interacts basally with the P2Y12 receptor in a 
PDZ-dependent manner with agonist addition increasing P2Y12 receptor / NHERF association 
that is required for agonist-stimulated receptor internalization(64). Intriguingly agonist-
dependent association of the P2Y12 receptor with NHERF was PDZ ligand-independent and 
required arrestin–receptor interaction. This study was therefore the first to directly 
demonstrate arrestin-dependent recruitment of NHERF1 to a receptor following agonist 
treatment. The in vivo significance of the NHERF–P2Y12 receptor interaction is ongoing in 
NHERF1 (-/-), NHERF2 (-/-) and NHERF1/2 (-/-) mice. These studies corroborate findings 
in cell line models showing that NHERF protein isoforms can regulate endogenous platelet 
P2Y12 receptor surface expression and activity (Cunningham et al., paper in preparation). The 
ability of other PDZ- and NHERF-interacting proteins to bind and regulate P2Y12 receptor 
function is currently under investigation.  
Variations in GPCR accessory proteins and their links to disease  
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The identification of genetic variants in key proteins that are essential for GPCR activity has 
also provided important insights into their functional significance.  There are many examples 
of genetic variations in accessory proteins that disrupt receptor function linked to disease. 
Examples include variants of Gβ subunits which are linked to essential hypertension, obesity, 
stroke, and myocardial infarction or variants of regulators G protein signalling (RGS) protein 
that confer risk for essential hypertension through changes in dopamine D1 receptor-
mediated kidney function (reviewed in (66). 
In relation to GRKs, which are established regulators of GPCR activity and traffic, both 
human GRK2 and GRK3 genes appear to lack genetic variation in their coding regions whilst 
GRK4 and GRK5 possess variations that have significant functional impacts (reviewed in 
(67)). Variants of GRK4, altering dopamine D1 receptor-mediated kidney function, have been 
identified as playing a role in essential hypertension (68) (69). Expression of three GRK4 
SNPs (Arg65Leu, Ala142Val, and Ala486Val) increased basal phosphorylation of the 
dopamine D1 receptor and impaired receptor-mediated cAMP production (70). Further in 
vitro studies suggest that the GRK4 SNPs disrupt the function of dopamine D1 receptors (71) 
(72), increase blood pressure, and impair the diuretic and natriuretic effects of dopamine D1 
receptor stimulation (73).  In addition to abnormal desensitization of the dopamine D1 
receptor, GRK4 polymorphisms are associated with increased expression of the angiotensin II 
type 1 receptor, which is another regulator of sodium load (74).  
A GRK5 variant (Leu41Gln), which displays an enhanced ability to promote agonist-
dependent β1 and β2 adrenoceptor desensitization and internalization,  has been shown to be 
involved in accelerated termination of β-adrenoceptor-induced cardiac contractility, improved 
protection against cardiac β-adrenoceptor overstimulation, better response to β-blockers and 
improved survival in heart failure (75,76). Interestingly in GRK5, this polymorphism is 
adjacent to a calmodulin-binding domain (77) which, following calcium-calmodulin binding, 
is reported to inhibit GRK5 catalytic activity towards receptors. 
Beyond GRKs, variations in other proteins known to regulate GPCR traffic have also been 
reported.  Unlike the examples of GRK isoforms above, GPCRs share common endocytic 
trafficking of many cell surface expressed proteins. Therefore it is perhaps not surprising that 
specific mutations in key regulatory machinery components have more global effects on a 
plethora of cell surface cargo cell rather than just specific GPCRs. For example, sorting nexin 
27 (SNX27) is a known regulator of endosomal recycling of specific PDZ ligand–containing 
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cargo proteins including a number of GPCRs such as the β2-adrenoceptor, 5HT2 receptor and 
parathyroid hormone receptor (78-80).  Detailed proteomic analysis conducted in mammalian 
cell lines has revealed that a loss of SNX27 expression results in the downregulation of 
multiple membrane proteins (81).  Recent evidence has linked mutations in the SNX27 gene 
to Down’s syndrome and infantile myoclonic epilepsy (82) (83).  The molecular mechanism 
of Down's syndrome (DS) pathogenesis, particularly cognitive defects in DS mice models, 
are thought to be due to loss of SNX27 expression and the subsequent downregulation of 
membrane glutamate NMDA and AMPA receptors(82).  
Similarly mutations in the GTPase dynamin 2, which again regulates the membrane traffic of 
multiple cell surface proteins including that of GPCRs, are associated with a number of 
disorders including Charcot–Marie– Tooth (CMT), peripheral neuropathy and centronuclear 
myopathy (CNM) (84,85). These two genetically heterogeneous disorders, which are both 
associated with general skeletal muscle weakness, have differing pathophysiological origins.     
Intriguingly close examination of the location of specific mutations in dynamin-2 revealed 
that most CNM mutations cluster in the interface between the dynamin mid-domain and 
pleckstrin homology domain of dynamin-2, thus altering the autoinhibitory interface between 
these domains thereby supporting a gain-of-function mechanism (86). The CMT mutations 
meanwhile are predominantly located on phosphoinositide-binding PH domain loops which 
are essential for targeting dynamin-2 to the plasma membrane (87).   Given that the dynamin-
2 knockout mouse is embryonic lethal (88), when combined, these studies suggest that 
mutations found in humans do not completely abolish dynamin-2 protein function, but rather 
involve subtle functional changes that lead to the progressive pathologies seen in CMT and 
CMN.  Notably the examples of both SNX27 and dynamin-2 have validated the key 
physiological importance of these proteins and helped to validate the functional significance 
of key domains predicted to regulate their biology.  
Intriguingly given that arrestins play keys roles in receptor biology, very few genetic 
polymorphisms have been identified (67). Some evidence has emerged that associates non-
coding variations in the non-visual arrestin gene with the risk of developing major depressive 
disorder (89) and the pathogenesis of Alzheimer's disease (90).  So far coding polymorphisms 
with significant functional impact have only been discovered in the visual arrestin-1 gene, 
which lead to visual disorders (e.g., Oguchi’s disease(91), night blindness or retinitis 
pigmentosa(92)). Given both the physiological importance of the arrestin family in the 
regulation of the majority of GPCRs and that there are only two isoforms of the non-visual 
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arrestins, perhaps it is not surprising that evolution may not have allowed for high levels of 
genetic variation of these proteins seen in GPCRs.  
A number of SNPs linked to platelet GPCR function and traffic have been identified during 
the course of the GAPP study (unpublished data). These include variants in dynamin-2 and 
NHERF1. Further study is now required to determine the functional significance of these 
SNPs in relation to platelet GPCR function. 
Conclusions and future perspectives 
As highlighted above with studies on the P2Y12 receptor, the investigation of naturally 
occurring GPCR variants continues to provide invaluable insights into the role of specific 
receptors as genetic risk factors for disease and the prediction of altered drug response.   
Mutated forms of GPCRs resulting in the disruption of receptor function are associated with a 
wide variety of human genetic diseases, including mild platelet bleeding disorders.  In human 
platelets such naturally occurring variations have provided a unique opportunity to study 
amino acid substitutions endogenously expressed in human tissue.  In this regard, platelets 
have a distinct advantage over other cell types in that they can be taken repeatedly and with 
relative ease from patients and family members.  Monogenic disorders resulting from 
disrupted GPCR function and signalling provide a unique window on receptor function.  This 
complements the plethora of data available from in vitro studies of variant receptors that have 
assigned structure-function relationships to particular receptor motifs.  For example, in 
relation to the P2Y12 receptor rare variants, disrupting either the DRY or PDZ motifs have 
both been shown to affect endogenous receptor traffic and function in platelets.  Such 
essential “in vivo” validation has enabled the full translation of our knowledge and 
understanding of receptor traffic in cell line studies into relevant human biological systems.   
The identification of naturally occurring variants in accessory proteins that regulate GPCR 
traffic and function is ongoing. Inherent difficulties have limited our ability to translate our 
current understanding of the role of specific molecular regulators of receptor function from 
cell expression studies into animal models and then into man. For example significant 
differences in cell machinery, membrane trafficking and receptor expression levels exist in 
individual cell types. Further, technologies emerging from next-generation sequencing 
continue to generate significant datasets for integrating genomic information into 
pharmacogenomic studies. For example RNA-sequencing, which makes use of  next-
generation sequencing to assess RNA presence and quantity at a given time will enable the 
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simultaneous profiling of multiple readouts including splice variants, expressed genes and 
RNA-edited isoforms. Such developments will significantly add to the already large list of 
protein variants, including those in GPCRs and their regulators identified over the past two 
decades. Whether specific genetic variations in key regulators of GPCR activity and traffic 
will provide an adjunct to the conventional routes of translating in vitro cell line studies into 
an in vivo physiologically relevant setting remains a potentially exciting opportunity to be 
fully realized.   
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